Anixa Biosciences (NASDAQ:ANIX) Azioni

ANIXA BIOSCIENCES INC

Anixa Biosciences

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Anixa Biosciences Inc

Mizuho analyst James Lee maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Outperform and lowers the price target from $230 to $205.

News

Price Target

Analyst Ratings

GOOGL

Mizuho Maintains Outperform on Alphabet, Lowers Price Target to $205

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW.png" alt="" class="wp-image-10060" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
As smart driving features trickle down to budget cars, the balance of power is shifting to automakers and away from their technology suppliers
China's autonomous driving industry is undergoing a major power shift. As "smart driving equality" emerges as the dominant narrative, a quiet revolution is underway — transitioning the industry from one limited to luxury cars to one with mainstream capabilities across the entire automotive sector.
Major Chinese automakers like&nbsp;BYD&nbsp;(1211.HK; 002594.SZ),&nbsp;NIO&nbsp;(NIO.US; 9866.HK),&nbsp;XPeng&nbsp;(XPEV.US; 9868.HK) and AITO are no longer confining their advanced autonomous driving functions to flagship models. To the contrary, features like navigation on autopilot (NOA), automated parking and city pilot are being rapidly rolled out across mid- and lower-end models priced below 200,000 yuan ($27,400).
While not the first to do so, BYD's launch of its high-level DiPilot system on models costing below 100,000 yuan at the beginning of this year marked a turning point—confirming that the era of smart driving equality had truly arrived.
"In the automotive sector, we believe that full-scale intelligentization will strengthen the global leadership of Chinese brands," said BYD founder Wang Chuanfu. "This is a show of confidence from China's auto industry, and reflects the confidence of Chinese technology."
Historically, high-level autonomous driving was a high-margin business, relying on premium hardware like LiDAR, HD cameras, domain controllers, and powerful chips — typically reserved for luxury models. But as smart driving becomes more accessible, automakers are increasingly taking control of core technologies to protect their profit margins.
BYD's DiPilot, XPeng's XNGP,&nbsp;Li Auto's (LI.US; 2015.HK) AD Max, and Huawei's ADS 2.0 illustrate this shift. Automakers are building their own algorithm teams, mapping systems, and even managing data annotation and simulation training in-house. As a result, upstream suppliers are being pushed to the sidelines, downgraded from solution providers to low-margin parts vendors.
Suppliers like&nbsp;RoboSense&nbsp;(2498.HK) are now offering low-cost solid-state LiDAR and modular solutions.&nbsp;Hesai&nbsp;(HSAI.US) is co-developing customized sensors with automakers.
For suppliers, this is a fight for survival. Without core technologies or the ability to scale, many small and mid-sized vendors face an uphill battle, and are surviving only with razor-thin margins. Only those with system integration, algorithm coordination, and global delivery capabilities are likely to endure.
Behind the push to make advanced autonomous driving available to all lies a quiet industry reshuffling and a redistribution of power. The real winners will be those companies that can not only manufacture vehicles but also master the soul of intelligent driving.

Equities

Travel

Opinion

Tech

XPEV

Smart Driving Equality: A Battle For Control Of An Emerging Industry

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Buy and lowers the price target from $50 to $37.

Reiteration

GMAB

HC Wainwright & Co. Reiterates Buy on Genmab, Lowers Price Target to $37

On Wednesday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) breast <a target="_blank" href="https://www.benzinga.com/exclusives" rel="noreferrer noopener">cancer vaccine technology</a>.
Cleveland Clinic has exclusively licensed the patent and others related to this technology to Anixa Biosciences. The patent will expand the scope of immunogenic compositions utilized in Anixa's breast cancer vaccine.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44471206/exclusive-anixa-biosciences-inks-letter-of-intent-with-austria-based-verdi-solutions-to-develop-ai-guided-personalized-cancer-vaccines" rel="noreferrer noopener">EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines</a>
This newly allowed patent covers methods of immunizing patients against breast cancer by administering an immunogenic composition containing the human α-lactalbumin protein, a protein typically found in breast tissue during lactation but also expressed in certain breast cancers.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "This patent strengthens our intellectual property portfolio and highlights the novelty of our breast cancer vaccine. Our intellectual property portfolio includes multiple issued and pending patents in the U.S. and international jurisdictions."
In March, the USPTO issued a Notice of Allowance for a key patent application covering&nbsp;Anixa Biosciences <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44455186/exclusive-anixa-biosciences-poised-to-receive-us-patent-for-ovarian-cancer-vaccine" rel="noreferrer noopener">ovarian cancer vaccine technology</a>.
The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and treatment.
Anixa's ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute.
The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response.
Price Action: ANIX stock closed at $2.38 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44698946/cell-therapy-maker-legend-biotech-an-attractive-opportunity-in-unpredictable-times-analyst" target="_blank" rel="noreferrer noopener">Cell Therapy Maker Legend Biotech Is An ‘Attractive Opportunity' Due To No Material Tariff Exposure: Analyst</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

ANIX

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

EXCLUSIVE: Anixa Biosciences Tells Benzinga 'Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach'

EXCLUSIVE: Anixa Biosciences Tells Benzinga Co. Receives Notice Of Allowance From US Patent And Trademark Office For Patent Covering Breast Cancer Vaccine Technology

Morgan Stanley analyst Vincent Sinisi maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Equal-Weight and lowers the price target from $125 to $113.

Morgan Stanley Maintains Equal-Weight on RPM Intl, Lowers Price Target to $113

Morgan Stanley analyst Alex Straton maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Equal-Weight and lowers the price target from $17 to $16.

LEVI

Morgan Stanley Maintains Equal-Weight on Levi Strauss, Lowers Price Target to $16

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) with a Buy rating and announces Price Target of $10.

Initiation

BNGO

HC Wainwright & Co. Initiates Coverage On Bionano Genomics with Buy Rating, Announces Price Target of $10

21Shares, one of the largest issuers of <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43742669/a-dogecoin-etf-approval-in-2025-is-becoming-increasingly-likely-polymarket-traders-speculate">crypto exchange-traded products</a> (ETPs), has officially launched the 21Shares Dogecoin ETP, the first Dogecoin-backed product endorsed by the Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) Foundation.
What Happened: The product went live today, with <a href="https://www.21shares.com/en-eu/product/doge">listing</a> on Swiss exchanges under the ticker DOGE.
The Dogecoin ETP offers exposure to the sixth-largest cryptocurrency by market capitalization, which closed 2024 valued at $46 billion—on par with legacy brands like General Motors.
The ETP enables both institutional and retail investors to gain direct access to Dogecoin through their bank or brokerage accounts, without needing to handle digital wallets or private keys.
"In partnership with House of Doge, we're excited to introduce the only Dogecoin ETP endorsed by the Dogecoin Foundation," 21Shares announced in a <a href="https://x.com/21Shares/status/1909876206020837776">statement</a> on social media. "Here's to the meme that made it."
The product has an annual fee of 2.5%, a net asset value of $5.00 per unit, and is not currently eligible for lending. 
The initial assets under management total $1.2 million, with 240,000 securities outstanding.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44703305/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">Bitcoin Is A &#8216;More Liquid And Higher Volatility Version Of Gold&#8217;: Bernstein</a>
Why It Matters: Dogecoin, launched in 2013 as a lighthearted take on cryptocurrencies inspired by the viral &#8220;Doge&#8221; meme, has since grown into a recognized global payments solution.
The currency's accessibility and loyal user base have helped transform it from a cultural phenomenon into a practical gateway for crypto adoption.
21Shares' listing provides investors with a structured and regulated way to gain exposure to Dogecoin without having to directly purchase or manage the token via a crypto wallet. 
This approach is increasingly popular among traditional investors looking for simplified access to digital assets.
Dogecoin's growth has also been propelled by a strong, socially-driven community known for charitable initiatives and open participation. 
Community-led campaigns such as Doge4Water, which raised funds in 2014 to provide clean water infrastructure in Kenya, reflect the grassroots ethos behind the token.
The 21Shares Dogecoin ETP launch marks another step in the maturation of meme-driven cryptocurrencies into investable financial instruments, as regulators and traditional institutions respond to continued demand for accessible crypto investment vehicles.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696653/how-bitcoin-will-go-from-65000-to-225000-in-2025">How Bitcoin Will Go From $65,000 To $225,000 In 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

MSFT

21Shares Launches Dogecoin Fund Backed By Dogecoin Foundation

Morgan Stanley analyst Brian Wilczynski initiates coverage on Atlantic Union Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUB#NYSE">AUB</a>) with a Equal-Weight rating and announces Price Target of $32.

Morgan Stanley Initiates Coverage On Atlantic Union Bankshares with Equal-Weight Rating, Announces Price Target of $32

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

Evercore ISI Group analyst Elizabeth Anderson downgrades Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) from Outperform to In-Line and lowers the price target from $6 to $4.

Downgrades

HCAT

Evercore ISI Group Downgrades Health Catalyst to In-Line, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and maintains $40 price target.

RNAC

HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

BMO Capital analyst John McNulty maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Outperform and lowers the price target from $154 to $126.

BMO Capital Maintains Outperform on RPM Intl, Lowers Price Target to $126

Baird analyst Ghansham Panjabi maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Neutral and lowers the price target from $125 to $110.

Baird Maintains Neutral on RPM Intl, Lowers Price Target to $110

Piper Sandler analyst Mike Lavery upgrades Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) from Neutral to Overweight and raises the price target from $35 to $40.

Upgrades

Piper Sandler Upgrades Keurig Dr Pepper to Overweight, Raises Price Target to $40

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on <a href="https://in.benzinga.com/markets/25/04/44627820/trumps-reciprocal-tariffs-on-india-exempt-pharma-easing-mark-cubans-price-hike-concerns">pharmaceuticals imported from foreign countries.</a>
What Happened: President Trump, on Tuesday, disclosed plans for a &#8220;major tariff&#8221; on foreign pharmaceuticals. Trump is hopeful that this move will prompt drug companies to shift their operations to the U.S., <a href="https://www.theguardian.com/australia-news/2025/apr/09/donald-trump-flags-major-tariff-on-pharmaceuticals-as-us-senator-criticises-whack-on-australia">reported</a> The Guardian.
&#8220;We&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals&#8230; when they hear that they will leave China, they will leave other places because&#8230; most of their product is sold here,&#8221; Trump expressed at a National Republican Congressional Committee dinner.
Despite exempting pharmaceuticals from the recent round of reciprocal tariffs, Trump has been hinting for a long time that the drug industry would be a target. The President is of the view that the tariff will drive drug companies to return to the U.S., considering it is a significant market for their products. &#8220;The advantage we have over everybody is that we&#8217;re the big market. So we&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals,&#8221; Trump added.
The President, however, did not divulge any specifics regarding the tariff increase or its potential impact.
Pharmaceutical stocks across the globe, including GlaxoSmithKline, Sanofi and India&#8217;s Teva Pharmaceuticals, tumbled on Wednesday.
In the U.S. pharmaceutical stocks, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) declined 3.5%, while Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) lost 3.2%. AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 1.35%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) dropped 2.94% and 2.75%, respectively, during the Wednesday pre-market trading session.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44706492/trump-predicts-tremendous-thundering-landslide-in-2026-midterms-says-tariffs-will-help-republicans-win-bi" target="_blank" rel="noreferrer noopener">Trump Predicts &#8216;Tremendous, Thundering Landslide&#8217; In 2026 Midterms, Says Tariffs Will Help Republicans Win Big</a>
Why It Matters: The $1.7 trillion revenue prescription drug industry has demonstrated a strong resilience to tariffs. The U.S., being the largest and most profitable market globally for prescription drugs and generic products, imports most of these from overseas. In 2024, drug imports reached $213 billion, more than two and a half times the total 10 years earlier. The proposed tariff could, in theory, help bring business back onshore.
However, companies like&nbsp;AstraZeneca Plc and&nbsp;Pfizer&nbsp;have extensive global manufacturing networks, including Ireland, Germany, Canada, the UK, and the U.S and are not restricted to India and China. Sources told Reuters that it could take up to 10 years to build and equip a factory in the U.S., due to stringent regulatory requirements from the U.S. Food and Drug Administration (FDA). Therefore, Trump&#8217;s tariff might necessitate drugmakers to overhaul a complex, expensive manufacturing system.
Meanwhile, after Trump indicated major tariffs on pharmaceuticals, EU drugmakers have urged European Commission President Ursula von der Leyen to take "rapid and radical action" to address the growing "risk of an exodus" to the U.S., following a meeting in Brussels.
<ul>
<li>READ MORE: <a href="https://benzinga.com/25/04/44705972/ford-motor-general-motors-to-witness-higher-demand-as-american-automotives-reap-the-fruit-of-protectionism-says-e" target="_blank" rel="noreferrer noopener">Ford, GM To Witness &#8216;Higher Demand&#8217; As American Carmakers Set To &#8216;Reap The Fruit Of Protectionism,&#8217; Says Expert: Here&#8217;s A List Of Potential Gainers And Losers From Trump Tariffs</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AMGN

Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Neutral.

RLYB

HC Wainwright & Co. Downgrades Rallybio to Neutral

Ancora Holdings, A Stockholder Of United States Steel, Announced That It Is Withdrawing Its Nomination Of Director Candidates For Election At The 2025 Annual Meeting Of Stockholders Due To Apparent Momentum Related To The $55 Per Share Sale To Nippon Steel Corporation

Press Releases

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Small Cap

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Comments

Anixa Biosciences

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO